Genomics – Genomic Testing Cooperative

Genomic Testing Cooperative (GTC) to Share 12 Ground-breaking Abstracts at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando

December 2, 2025

Lake Forest, CA — December 2, 2025 — Genomic Testing Cooperative (GTC), a leading provider of integrated DNA and RNA next-generation sequencing (NGS) solutions for hematologic tumors and liquid biopsy applications, today announced that its work and data will be presented in 12 abstracts at the ASH 2025 Annual Meeting

ASH22 Posters

December 13, 2022

GTC presented abstracts at ASH 2022 GTC’s posters from 2022 Convention of American Society of Hematology are now available to be downloaded. Please reach out with any questions. Download Poster Download Poster Want to explore more of our scientific content? Discover additional articles, videos, publications Search Search

Case Study: VEXAS Syndrome

June 8, 2022

Background VEXAS syndrome is a disease with inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene affecting the Met41 residue of the protein and resulting in decreased cellular ubiquitylation activity and hyperinflammation. This is an adults-onset fatal disease that may present as myelodysplastic syndrome, aplastic anemia

ASH21 Posters

December 14, 2021

AACR 23 Posters GTC’s posters from 2023 Convention of American Association for Cancer Research are now available to be downloaded. Please reach out with any questions. Predicting PD-L1 Status in Solid Tumors Using Transcriptomic Data and Artificial Intelligence Algorithms Download Poster The Molecular Landscape of Premenopausal Versus Postmenopausal Breast Cancer

GTC scientists contribute to major study published in Journal of Clinical Oncology: Prediction of outcome in CLL patients

October 8, 2020

GTC scientists collaborate with the NIH on a study just published in the Journal of Clinical Oncology. The publication is titled: Prediction of outcome in CLL patients treated with ibrutinib: development and validation of a four-factor prognostic model. You can read the article here (subscription required). Abstract: PURPOSE Randomized trials established the

Genomic Testing Cooperative Aims to Expand Clinical, Commercial NGS Access With Co-Op Model

August 26, 2020

Jul 23, 2020 | John Gilmore NEW YORK – As part of plans to establish a country-wide network of labs for minimizing the cost of sequencing, Genomic Testing Cooperative (GTC) has launched a joint venture with Hackensack Meridian Health (HMH) that will analyze clinical samples from patients with a variety

John Theurer Cancer Center/RCCA collaborate with GTC to internalize proprietary NGS DNA and RNA testing

May 27, 2020

John Theurer Cancer Center to Establish Next Generation Sequencing Laboratory for Precision Genomic Profiling of Cancers, Adapting Testing Developed for DNA and RNA IRVINE, Calif. and Hackensack, NJ, [May 27th, 2020] John Theurer Cancer Center (JTCC), at Hackensack Meridian Health Hackensack University Medical Center in New Jersey, and Genomic Testing Cooperative (GTC),

GTC was featured in the Orange County Business Journal again

February 26, 2020

GTC featured in the Orange County Business Journal on February 3, 2020

GTC was honored to be featured in the Orange County Business Journal

October 16, 2019

GTC featured in the Orange County Business Journal on September 30, 2019

Acute Lymphoblastic Leukemia

February 26, 2019

Order GTC Hematology Expression/Fusion Profile The GTC Hematology Expression/Fusion test provides actionable information for: 1) Determining Fusion and classification (Ph-Positive or Ph-Like)Acute lymphoblastic leukemia (ALL) is a heterogeneous disease with genomic alterations dominated by structural chromosomal abnormalities, particularly translocations. Most of the reported chromosomal translocations in ALL lead to the

Category: Genomics